Osimertinib and Plasma Genotyping

(3:38)

Osimertinib and the FLAURA Trial

(5:42)

New agents for EGFR+ NSCLC: osimertinib and beyond

(4:38)

LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLC

(1:39)

FLOWERS: osimertinib and savolitinib in MET aberrant, EGFRm NSCLC

(55)

Osimertinib and chemotherapy in EGFR+ lung cancer with TP53 and RB1 alterations

(1:44)

Neoadjuvant Osimertinib and Surgically Resectable EGFR+ - Targeted Therapies in Lung Cancer 2023

(2:11)

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

(6:1econd)

Osimertinib in T790M-Mutant Lung Cancer

(5:45)

FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib

(3:34)

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJM

(2:20)

Osimertinib + ipilimumab in EGFR-mutated NSCLC

(2:21)

Osimertinib, the Standard for EGFR+ NSCLC

(6:6)

Real world analysis of second-line osimertinib use for NSCLC in North West London

(2:11)

Osimertinib in Advanced Non–Small-Cell Lung Cancer

(2:20)

EGFR Mutated NSCLC Disease Progression on Osimertinib - 2022 Program: Targeted Therapies Forum

(3:20)

Osimertinib in EGFR-Positive NSCLC With Brain Metastases

(3:17)

Combination Therapy with Osimertinib for EGFR+ NSCLC - Targeted Therapies in Lung Cancer 2023

(2:44)

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

(3:17)

Resistance to Osimertinib in EGFR-Mutated NSCLC

(1:53)